Advertisement

Medical Oncology and Tumor Pharmacotherapy

, Volume 8, Issue 3, pp 189–201 | Cite as

Eradication of leukaemic marrow and prevention of leukaemia relapse with total body irradiation and bone marrow transplantation

  • Francesco Frassoni
Article
  • 17 Downloads

Abstract

A series of studies was carried out to determine the effect of allogeneic bone marrow transplantation (BMT) on leukaemia. The study aimed at two different, but strictly linked issues: (1) identification of the eradication capability of BMT, and (2) evaluation of the effect of BMT, both in preventing relapse and in producing long-term disease-free survival. Fifty-four patients allografted for leukaemia were evaluated at various intervals, after bone marrow transplantation, for the presence of host haemopoiesis using red-blood-cell and cytogenetic markers. Among 40 patients in remission, 10 showed functional host and donor haemopoiesis (mixed chimerism), while in 30, host haemopoiesis was never detected (complete chimerism). Seven of the 14 evaluable patients who relapsed showed the reappearance of host haemopoiesis at the time of relapse. The records of received doses of TBI indicate that patients who achieved mixed chimerism, either relapsing or not, received significantly lower doses than complete chimeras. However, some patients with complete chimerism received a TBI dose equivalent to the dose received by those with mixed chimerism, suggesting that the TBI dose is not the only factor determining the reappearance of host haemopoiesis. The data on chimerism and relapse suggest that there is heterogeneity in radiosensitivity between normal marrow cells and leukaemic cells, and further, within the different types of leukaemia. The incidence/severity of acute and chronic graft-vs-host disease (GvHD) was significantly higher in complete chimeras than in mixed chimeras suggesting that mixed chimerism may play a role in the development of tolerance; however, it could be the tolerance (i.e. absence of GvHD) which is responsible for the persistence of host haemopoietic cells. One-hundred-and-sixty-eight patients undergoing allogeneic bone marrow transplantation (BMT) for acute myeloid leukaemia (AML) and chronic myeloid leukaemia were analyzed for risk factor associated with relapse. All patients received marrow from an HLA identical sibling after preparation with cyclophosphamide 120mg/kg and total body irradiation (TBI) of 330 cGy on days -3, -2, -1. There was a difference of ±18% between the nominal total dose of 990 cGy and the actual received dose as indicated by dosimetric recordings. While interstitial pneumonitis had minimal impact on survival there was a considerable difference in the incidence of relapses. The incidence of relapse was higher in patients receiving less, than in patients receiving more than 1000 cGy respectively and this had a major impact on survival. However, transplant-related mortality was slightly higher in the group of patients receiving higher doses of TBI. These results suggest that a higher dose of TBI, within this schedule, produced long-term disease-free survival in the majority of acute myeloid leukaemia and chronic myeloid leukaemia with minor radiobiological side-effects which, however, tended to be higher as the TBI dose increased. Moreover, a small reduction of the dose may significantly increase the risk of relapse. In addition, the disease status significantly influences the probability of relapse and this is mainly seen in chronic myeloid leukaemia. Moreover, the prevention of graft-vs-host disease plays a relevant role both in relapse as well as in the transplant-related mortality. It is therefore concluded that fine tuning of the conditioning protocol, and of the therapy for graft-vs-host prevention, is needed to improve the results in allogeneic bone marrow transplant.

Key words

Leukaemia relapse Total body irradiation Bone marrow transplantation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rohatiner Z S, Lister T A: The treatment of acute myelogenous leukaemia, in Henderson E S, Lister T A (eds):Leukaemia, p. 485. W B Saunders Company, Philadelphia (1990).Google Scholar
  2. 2.
    Frassoni F, Repetto M, Podestà Met al.: Competitive survival/proliferation of normal and Phi-positive haematopoietic cells.Br J Haematol 63, 1135 (1986).CrossRefGoogle Scholar
  3. 3.
    Fearon E R, Burke P J, Shifter C Aet al.: Differentiation of leukemic cells to polymorphonuclear leukocytes in patients with acute non-lymphocytic leukemia.N Engl J Med 315, 15 (1986).PubMedGoogle Scholar
  4. 4.
    Frassoni F, Sessarego M, Bacigalupo Aet al.: Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukaemia.Br J Haematol 69, 471 (1988).PubMedCrossRefGoogle Scholar
  5. 5.
    Cunningham I, Gee T, Dowling Met al.: Results of treatment of Ph+ chronic myelogenous leukaemia: with an intensive treatment regimen (L-5 Protocol).Blood 53, 375 (1979).PubMedGoogle Scholar
  6. 6.
    Coloumbel L, Kalousek D K, Eaves C Jet al.: Long-term culture reveals chromosomally normal hemopoietic progenitors cells in patients with Philadelphia-chromosome positive chronic myelogenous leukaemia.N Engl J Med 304, 700 (1983).Google Scholar
  7. 7.
    Turhan A G, Humphries R K, Eaves C Jet al.: Detection of breakpoint cluster region-negative and non-clonal hematopoiesisin vitro andin vivo after transplantation of cells selected in cultures of chronic myeloid leukaemia marrow.Blood 76, 2404 (1990).PubMedGoogle Scholar
  8. 8.
    Goldman J M: Use of autologous stem cells in support of the intensive treatment of chronic myeloid leukaemia, in Deisseroth A B and Arlinghaus R B (eds), Vol. 13, p. 455. Marcel Dekker, New York (1991).Google Scholar
  9. 9.
    Sullivan K M, Weiden P L, Storb Ret al.: Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukaemia.Blood 73, 1720 (1989).PubMedGoogle Scholar
  10. 10.
    Horowitz M M, Gale R P, Sondel P Met al.: Graft- versus-leukaemia reactions after marrow transplantation.Blood 75, 555 (1990).PubMedGoogle Scholar
  11. 11.
    Marmont A M, Horowitz M M, Gale P Ret al.: T-cell depletion of HLA-identical transplants in leukaemia (submitted for publication).Google Scholar
  12. 12.
    International Bone Marrow Transplant Registry: Transplant or chemotherapy in acute myelogenous leukaemia?Lancet i, 1119 (1989).Google Scholar
  13. 13.
    Frassoni F, Srada P, Sessaregoet al.: Mixed chimerism after allogeneic marrow transplantation for leukemia: correlation with dose of TBI and graft-versus- host disease.Bone Marrow Transpl 5, 235 (1990).Google Scholar
  14. 14.
    Frassoni F, Scarpati D, Bacigalupo Aet al.: The effect of total body irradiation dose and chronic GvHD on leukaemic relapse incidence after allogeneic bone marrow transplantation.Br J Haematol 73, 211 (1989).PubMedCrossRefGoogle Scholar
  15. 15.
    Bacigalupo A, Corte G, Pittaluga A P, Frassoni F, Marmont A: Prevention of GvHD with BT 5/9: a randomized trial.Bone Marrow Transpl 1 (Suppl 1), 101 (1986).Google Scholar
  16. 16.
    Branch D R, Gallagher M T, Forman S J, Winkler K J, Petz L D, Blume K G: Endogenous stem cell repopulation resulting in a. mixed hemopoietic chim- erism following total body irradiation and marrow transplantation for acute leukaemia.Transplantation 34, 226 (1982).PubMedCrossRefGoogle Scholar
  17. 17.
    Appcrley J F, Jones L, Hale G, Waldmann H, Hows J, Rombos Y, Tsatalas C, Marcus R E, Goolden A W G, Gordon-Smith E C. Catovsky D, Galton D A G, Goldman J M: Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.Bone Marrow Transpl 1, 53 (1986).Google Scholar
  18. 18.
    Bretagne J, Vinaud M, Kuenz M, Cordonnier C, Flenni T, Vinci G, Goossens M, Vernant J P: Mixed blood chimerism in T cell depleted bone marrow transplantation recipients: evaluation using DNA polymorphism.Blood 70, 1692 (1987).PubMedGoogle Scholar
  19. 19.
    Petz L D, Yam P, Wallace B, Stock D, de Lange G, Knowlton R G, Brown V A, Donis-Keller HL Hill L R, Forman S J, Blume K G: Mixed hemopoietic chimerism following bone marrow transplantation for hematologic malignancies.Blood 70, 1331 (1987).PubMedGoogle Scholar
  20. 20.
    van Dijk B A, Drenthe-Shonk A M, Bloo A, Kunst V A J M, Janssen J T P. de Witte T J M. Erythrocyte repopulation after allogeneic bone marrow transplantation.Transplantation 44, 650 (1987).PubMedCrossRefGoogle Scholar
  21. 21.
    Goldman J M, Apperley J F, Jones L, Marcus R, Goolden A W G, Batchelor R, Hale G, Waldmann H, Reid C, Hows J, Gordon-Smith E C, Catovsky D, Galton D A G: Allogeneic bone marrow transplantation for chronic myelogenous leukaemia.New Engl J Med 314, 202–207 (1986).PubMedGoogle Scholar
  22. 22.
    Hill R S, Petersen F B, Storb R, Appelbaum F R, Doney K, Dahlberg S, Ramberg R, Thomas D E: Mixed hematologie chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with higher risk of graft rejection and lessened incidence of acute graft-versus-host disease.Blood 67, 811 (1986).PubMedGoogle Scholar
  23. 23.
    Sykes M, Sharabi Y, Sachs D H: Achieving alloen- graftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.Bone Marrow Transpl 3, 379 (1988).Google Scholar
  24. 24.
    Weiden P L, Flournoy N, Thomas E Det al.: Antileukemic effect of graft-versus-host disease in human recipients of alloseneic-marrow grafts.New Engl J Med 300, 1068 (1979).PubMedGoogle Scholar
  25. 25.
    Scarpati D, Frassoni F, Vitale Vet al.: Total body irradiation in acute myeloid leukaemia and chronic myelogenous leukaemia: influence of dose and dose- rate on leukemia relapse.Int J Radiat Oncol Biol Phys 17, 547 (1989).PubMedGoogle Scholar
  26. 26.
    Clift R A, Buckner C D, Appelbaum F Ret al.: Allogeneic marrow transplantation in patients with acute leukaemia in first remission: A randomized trial of two irradiation regimens.Blood 76, 1867 (1990).PubMedGoogle Scholar
  27. 27.
    Niederwieser D W, Appelbaum F R, Gastl Get al.: Inadverted transmission of donor’s acute myeloid leukaemia in bone marrow transplantation for chronic myeloid leukaemia.New Engl J Med 322, 1794 (1990).PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1991

Authors and Affiliations

  • Francesco Frassoni
    • 1
  1. 1.Centro Trapianti Midiollo OsseoDivisione EmatologiaGenovaItaly

Personalised recommendations